Hematology/Oncology

Top Story

Tyrosine kinase inhibitors lead to ‘dramatic’ improvements in CML

Tyrosine kinase inhibitors lead to ‘dramatic’ improvements in CML
September 28, 2016

The development of tyrosine kinase inhibitors for chronic myeloid leukemia, including imatinib, was spurred by an increased understanding of the disease’s genetics. Together, these advances have “dramatically” improved outcomes for patients with CML, according to Gabriela S. Hobbs, MD, of Massachusetts General Hospital.

 “The approval of imatinib (Gleevec, Novartis) was one of the most important changes in the way we treat cancer,” Hobbs told HemOnc Today. “It really was a watershed moment in oncology. It changed more than the way we think about CML and the way we treat CML – it changed our approach to many other cancers. It demonstrated that, if you understand the genetics of a disease, you can target it with therapies that are specific for those genetic mutations.”

Meeting News CoveragePerspective

Late toxicity comparable between extremely hypofractionated, conventional radiotherapy for prostate cancer

September 28, 2016
Treatment with extremely hypofractionated radiotherapy resulted in similar adverse events after 2 years as conventionally fractionated radiotherapy for men with…
Meeting News CoveragePerspective

Hypofractionated radiation therapy offers shorter treatment for poor-performance NSCLC

September 28, 2016
The use of accelerated hypofractionated radiation therapy produced equivalent OS and PFS outcomes as conventional radiation therapy in patients with non–small cell…
In the Journals

MRI bests ultrasound for early detection of HCC

September 28, 2016
Magnetic resonance imaging — as opposed to ultrasound — offers a significantly greater chance of detecting hepatocellular carcinoma early, according to a…
In the Journals Plus

Survivors of fusion-negative sarcoma at increased risk for second malignancies

September 28, 2016
Survivors of sarcoma demonstrated an increased risk for second malignant neoplasms, according to study results published in Cancer. Survivors of fusion-negative tumors
More News Headlines »
CME CNE CPE

Individualized Prophylaxis in Hemophilia

Support for this activity has been made possible through an educational grant from Bayer HealthCare Pharmaceuticals

This program will provide education for hematologists, nurses, pharmacists, and other healthcare providers involved in…
More »
Video
Meeting News Coverage

VIDEO: Combination of anti-PD-1 inhibitors with new immune-modulators produces ‘exciting’ results in solid tumors

August 31, 2016
More »
Featured
At Issue: Breast Cancer Resource Center

At Issue: Breast Cancer Resource Center

CME Video

NSCLC Treatment on Target: Examining New Evidence and Advances

This activity is supported by an educational grant from Genentech, Inc. and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Eighty five percent of lung cancers are non-small…
More »
Current Issues
View the Current Issue
HemOnc Today
morganatic-roan
morganatic-roan